logo
Plus   Neg
Share
Email

MorphoSys Says Court Grants Its Request To Add Second Patent In Lawsuit

MorphoSys AG (MPSYY.PK) said that it has added a second patent with US Patent Number 9,200,061 to its lawsuit against Janssen Biotech, and Genmab, A/S. This patent claims methods of treating hematologic cancer associated with the undesired presence of CD38-positive cells by administering antibodies that bind to a specific region of the target molecule, CD38.

In a hearing that took place on February 6, 2017 the District Court granted MorphoSys's request to add the 9,200,061 patent to the case.

On April 4, 2016 MorphoSys filed a lawsuit in the United States District Court of Delaware against Janssen Biotech, and Genmab, A/S for patent infringement of U.S. Patent Number 8,263,746.

By its complaint, MorphoSys seeks redress for infringement by Janssen's and
Genmab's daratumumab, a CD38-directed monoclonal antibody indicated for the
treatment of certain patients with multiple myeloma.

Janssen Biotech obtained FDA approval on daratumumab and markets the product as Darzalex in the U.S. and other countries. MorphoSys continues to develop MOR202, its own investigational human antibody to CD38, for the treatment of cancer, including multiple myeloma.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Johnson & Johnson's (JNJ) Covid-19 vaccine is expected to be back on track as early as this weekend as a decision is expected after the advisory panel meeting of the U.S. Centers for Disease Control and Prevention (CDC) slated on April 23, according to Dr. Anthony Fauci, the chief medical adviser to President Joe Biden. MK-4482, the experimental antiviral drug for COVID-19, showed promise to prevent and treat SARS-CoV-2 infection in hamster study, according to the scientists of National Institutes of Health or NIH. The drug significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection. MK-4482, delivered orally, is now in Phase 2 and 3 human clinical studies. Beverages giant Coca-Cola reported a 19 percent decline in profit for the second quarter from last year as a revenue growth of 5 percent and improved margins were offset by higher income taxes and interest expense. However, adjusted earnings per share and revenues topped analysts' expectations. The company also maintained its adjusted earnings and organic revenue growth outlook for fiscal 2021.
RELATED NEWS
Follow RTT